CERVICAL SCREENING IN PRACTICE: OPTIMISING HPV SELF-COLLECTION



Dr Rebecca Starkie













Gold Coast PHN, 10 July 2024


























ACKNOWLEDGEMENT OF TRADITIONAL OWNERS





OVERVIEW



- Setting the scene eliminating cervical cancer in Australia
- Universal self-collection addressing inequity
- Supporting choice what you and your patients need to know
- Self-collection and routine screening
- Other situations where self-collection can be offered





THE GLOBAL EFFORT TO ELIMINATE CERVICAL CANCER




Goal: <4 per 100,000 women in every country within the next 100 years

The World Health Organization officially launched the Global Strategy to Accelerate the Elimination of Cervical Cancer in November 2020.

Australia has answered the call to develop a National Elimination Strategy.

ELIMINATING CERVICAL CANCER IN AUSTRALIA





Elimination = <4 cases / 100,000

Modelling suggests that with HPV vaccination and HPV-based cervical screening, Australia can achieve the WHO's Global Strategy goal to eliminate cervical cancer as a public health problem by **2035**

Source: Hall MT et al (2019)

https://www.thelancet.com/journals/lanpub/article/PIIS2468-

2667(18)30183-X/fulltext

AUSTRALIA'S VISION



An Australia where preventable cervical cancer is a disease of the past, in which Australia's diverse communities have equitable access to information and to culturally safe and inclusive vaccination, screening and treatment services.

Priority Populations:





Culturally and linguistically diverse people



People who are LGBTQ+ and people who are intersex



People with disability




People living in rural and remote areas



ELIMINATION MUST INCLUDE ALL





Cervical cancer incidence, mortality and 5-year survival in Aboriginal and Torres Strait Islander women and non-Indigenous women

Source: AIHW 2018. Cancer in Aboriginal & Torres Strait Islander people of Australia. Web Report

ADDRESSING INEQUITY

In Australia, cervical cancer inequities exist depending on:





WHO YOU ARE





WHERE YOU LIVE







SOCIO-ECONOMIC STATUS





Source: Australian Institute of Health and Welfare 2020. National Cervical Screening Program monitoring report 2020. Cancer series 130. Cat. no. CAN 138. Canberra: AIHW.

UNDERSCREENING
IS A RISK FACTOR
FOR CERVICAL
CANCER



Source: Australian Institute of Health and Welfare 2021. National Cervical Screening Program monitoring report 2021. Cancer series 134. Cat. no. CAN 141. Canberra: AIHW.

NATIONAL CERVICAL SCREENING CAMPAIGN





An Australian Govt funded national campaign is coming in September 2024!

Targeting Aboriginal and Torres Strait Islander and CALD people, but likely to bleed into mainstream as well

Likely to drive patient demand for self-collection.

Are YOU ready to support your patients to access this option?



The Australian Government has funded the ACPCC to deliver healthcare provider education to ensure they are ready to meet demand.

SELF-COLLECTION IS HIGHLY ACCEPTABLE







Source: Saville et al (2018). Self-Collection for Under-Screened Women in a National Cervical Screening Program: Pilot Study, Curr. Oncol



SUPPORTING YOUR PATIENTS TO MAKE THE CHOICE

Self collection - WHAT IS IT?



HPV SELF-COLLECTION: WHAT IS IT?



Involves taking a sample from the vagina using a simple swab

Provides an alternative to the speculum examination required for a traditional cervical screening test

SELF-COLLECTION







WHO CAN SELF-COLLECTION BE OFFERED TO?



Anyone who requires just an HPV test at any point on the cervical screening pathway including:

Routine 5 yearly screening

1 year follow-up after HPV (not 16/18) detected, cytology normal or low grade (Intermediate risk)

1 year follow-up after normal or CIN1 colposcopy

CERVICAL SCREENING PATHWAY (CLINICIAN COLLECTED) OR SELF-COLLECTED) Oncogenic HPV test with partial genotyping LEGEND LBC (reflex or collect cervical sample if self-collection was used) LBC (reflex or collect at colposcopy) Retest HPV Test result in 6 weeks Recommendation LBC pHSIL LBC res. tt or Woman's risk of developing cervical cancer precursors within the next five years Retest for LBC Refer for colposcopic only in 6 weeks Intermediate Higher of to colposcopy is women 50+ ye . Aboriginal and/or To (16/18)· women overdue for screening by Self-collection is an option at least 2 years at initial screen LBC (reflex or collect cervical sample if self-collection was used) LBC (reflex or collect Retest HPV for routine screening and at colposcop, in 6 weeks at the 12 or 24 month LBC pHSIL LBC result or follow-up test after an intermediate risk result Retest for LBC only in 6 weeks (HPV (not 16/18), LBC normal, LSIL, Refer for pLSIL) LBC (reflex or collect at colposcopy) National cervical screening program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. 5-yearly screening Available at https://www.cancer.org.au/clinical-guidelines/cervical-cancer/cervical-cancer-screening

WHO CANNOT BE OFFERED SELF-COLLECTION?



These patients require a co-test

Symptoms that require further investigation to exclude cervical cancer

- Unexplained vaginal bleeding (Post coital bleeding, inter-menstrual bleeding, post menopausal bleeding)
- Unexplained, persistent or unusual vaginal discharge
- Not dyspareunia as an isolated symptom

Test of Cure

- After treatment following CIN2/3 on biopsy
- Require annual co-test until two consecutive negative co-test

History of adenocarcinoma in situ (AIS)

• Require annual co-testing surveillance indefinitely

DES exposure in utero

• Require annual vaginal and cervical co-test as well as colposcopy

BEFORE OFFERING SELF-COLLECTION <



Check for symptoms

Check screening history



UPCOMING GUIDELINE UPDATES



Test of Cure

New Cervical Screening Clinical Guidelines are expected to be published later in 2024.

This means that self-collection will be an option for those people who are completing Test of Cure.

The updated guidelines will recommend that Test of Cure becomes an HPV test.



Access the cervical screening guidelines via the Cancer Council Australia website www.cancer.org.au/clinical-guidelines/cervical-cancer/cervical-cancer-screening



SUPPORTING YOUR PATIENTS TO MAKE THE CHOICE

Self collection – HOW IS IT COLLECTED?

PROCESSING OF SELF-COLLECTED SAMPLES



The most commonly used device for self-collection in the NCSP is the:

Copan FLOQswab (red top) flocked swab 552C or 552C.80



Make sure you check with your pathology lab!

SELF-COLLECTION IS EASY TO DO





















STEP ONE

- Lower your underwear
- Twist the swab cap and pull out the swab
- Look at the swab and note the red mark closest to the soft tip

STEP TWO

- Get in a comfortable position. You can stand, sit or lie down
- Insert the swab into your vagina, aiming to insert up to the small red mark (this is about the same length as your index finger)

STEP THREE

- Rotate the swab gently for at least 10 seconds
- Then remove the swab
- It should not hurt

STEP FOUR

- Place swab back in the tube
- Return the tube to your healthcare provider
- Ensure the date you take the test is written on the swab tube
- Ensure the tube is labeled with your surname, first name and date of birth

These instructions are available in 20 different languages.

Available on the ACPCC website:

acpcc.org.au

Practitioners

→ Clinical
Resources

Your healthcare provider will give you the swab. If you have any questions, ask your healthcare provider.

SETTINGS WHERE SELF-COLLECTION CAN BE PERFORMED





All cervical screening is ordered and overseen by a healthcare professional.

appropriate

Collection can happen in any setting the requesting practitioner believes is

Patients should be encouraged to collect a sample at the clinic, if possible

No need to observe the patient, but you can help if needed

COMPARING THE OPTIONS



		Clinician collected	Self-collected	
	Identifies HPV infection	Yes - Cervical cells	Yes - Vaginal cells	
	Liquid based cytology and co-test possible	Yes	No	
90%	No HPV detected ~90% for CSTs	Return in 5 years	Return in 5 years	
2%	HPV 16/18 detected ~2% for CSTs	Refer to colposcopy	Refer to colposcopy	
6%	HPV (not 16/18) detected ~6% for CSTs	LBC performed on original sample	Return for clinician collected cervical sample for LBC	
?	Unsatisfactory HPV test	Repeat in 6 weeks	Repeat at earliest convenience	



SUPPORTING YOUR PATIENTS TO MAKE THE CHOICE

What you and your patients need to know

SELF-COLLECTION IS ACCURATE



For HPV assays based on polymerase chain reaction (PCR), testing on self-collection is as clinically sensitive and specific as clinician-collection for CIN2+ and HPV.

2018

Detecting cervical precancer and reaching under-screened women by using HPV testing on self samples: updated meta-analyses.¹

2020

Analytical performance of HPV assays on vaginal self-collected vs practitioner-collected cervical samples: the SCoPE study.²

FLOQSWabs COPAN

Sources

- 1. Arbyn et al, BMJ, 2018
- 2. Saville et al, Journal of Clinical Virology, 2020

SELF-COLLECTION IS SAFE



Safety controls on HPV test ensure that samples taken incorrectly, or affected by contaminants are reported as 'unsatisfactory' rather than 'negative'

Cellularity control

Ensures enough cellular material is present in the sample

Assay failure control

Contaminants, such as blood, microbial infection or lubricant, may inhibit the PCR reaction and therefore the ability of an assay to detect HPV



LIKELIHOOD OF RETURN



Self-collected CST



HPV (not 16/18) detected ~6%

Return for clinician collected cervical sample for LBC.

The incidence of HPV (not 16/18) is highly age dependent (NCSR data general population).

25-29 years	17%	50-54 years	4%
30-34 years	10%	55-59 years	3%
35-39 years	6%	60-64 years	3%
40-44 years	5%	65-69 years	3%
45-49 years	4%		



SUPPORTING YOUR PATIENTS TO MAKE THE CHOICE

Other points in the pathway where self-collection can be offered


EXIT TESTING

Patients can be discharged from the NCSP if they are aged 70-74 years and have a screening test at which oncogenic HPV is not detected

Direct referral to colposcopy if ANY HPV found

 If the sample was self-collected, there is no need to return for a cervical sample for LBC (this will be collected at the time of colposcopy)







Self-collection is an option at the 12 or 24 month follow-up test after an intermediate risk result (HPV (not 16/18), LBC normal, LSIL, pLSIL)



CERVICAL SCREENING PATHWAY (CLINICIAN COLLECTED OR SELF-COLLECTED)

Oncogenic HPV test with partial genotyping LBC (reflex or collect cervical sample if self-collection was used) LBC (reflex or collect LBC (reflex or collect cervical sample if self-collection was used LBC (reflex or collect


Self-collected follow-up test

 Of people attending for a follow-up test, 12 months after an Intermediate risk result:

~60% will again test positive for HPV (not 16/18)



CERVICAL SCREENING PATHWAY (CLINICIAN COLLECTED OR SELF-COLLECTED)




Self-collected follow-up test

- However, direct referral to colposcopy recommended for:
 - Women 50+ years
 - Aboriginal and/or Torres Strait
 Islander women
 - Women overdue for screening by at least 2 years

Therefore, no need for these groups to return for LBC if HPV (not 16/18) detected at this test



CERVICAL SCREENING PATHWAY (CLINICIAN COLLECTED OR SELF-COLLECTED)



Self-collected follow-up test

 Of people attending for another follow-up test, 24 months after an intermediate risk result:

Anyone with **ANY** HPV detected at this test will be referred directly to colposcopy





CASE STUDY

Bringing it all together



CASE STUDY: POLL QUESTION 1





Lauren is a 29yo woman She is pregnant

She has never had cervical screening, and she is anxious about the process. She has no symptoms of concern.

Poll Question 1: Can you offer self-collection?

YES

NO





Lauren is a 29yo woman She is pregnant

She has never had cervical screening, and she is anxious about the process. She has no symptoms of concern.

Poll Question 2: What are some of the things you might discuss with Lauren to help her make her choice?

Self-collection is just as accurate as clinician collected sampling

There is about a 4% chance she'll have to return for LBC

There is about a 17% chance she'll have to return for LBC

If she doesn't do it right, she could get a false negative result





Lauren is a 29yo woman She is pregnant

She has never had cervical screening, and she is anxious about the process. She has no symptoms of concern.

Lauren chooses self-collection but refuses to do it in the surgery and asks if she can take the swab home.

Poll Question 3: Is this allowed by Medicare?

YES

NO

CASE STUDY





Lauren is a 29yo woman She is pregnant

She has never had cervical screening, and she is anxious about the process. She has no symptoms of concern.

You are pleased to see that she has done the test as required and dropped it in.

The result is HPV (not 16/18) positive





Lauren is a 29yo woman She is pregnant

She has never had cervical screening, and she is anxious about the process. She has no symptoms of concern.

Poll Question 4: What is the correct follow up?

Return for co-test in 1 year

colposcopy because she has never been screened

Return for cytology

CASE STUDY





Lauren is a 29yo woman She is pregnant

She has never had cervical screening, and she is anxious about the process. She has no symptoms of concern.

Lauren returns for a speculum examination to obtain a sample for cytology. Her cytology results are normal and she's recommended to return for a repeat test in 1 year.

She comes back for an appointment for a post natal check a year later. You mention that she is due for her 12-month follow-up test but she is again anxious and reluctant to have a speculum examination.





Poll Question 5: What do you talk to her about to help her choose this time?

She can't self-collect as her last test was abnormal


She can self-collect. If HPV is found, she will go to colp

She can self-collect.
There's a ~60% chance
she'll need to return for
LBC

THE INTERMEDIATE RISK PATHWAY



CERVICAL SCREENING PATHWAY (CLINICIAN COLLECTED OR SELF-COLLECTED)



Self-collected follow-up test

- However, direct referral to colposcopy recommended for:
 - Women 50+ years
 - Aboriginal and/or Torres Strait
 Islander women
 - Women overdue for screening by at least 2 years

Therefore, no need for these groups to return for LBC if HPV (not 16/18) detected at this test

National cervical screening program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Available at https://www.cancer.org.au/clinical-guidelines/cervical-cancer/cervical-cancer-screening



RESOUCES TO SUPPORT YOU AND YOUR PATIENTS



CERVICAL SCREENING: Supporting your patients to make the choice









Identifies HPV infection? Yes Yes No Indicated for Those who are eligible and due or overdue for cervical screening, including during pregnancy Other points in the pathway where only an HPV test is required. Patients who have postcoital, intermenstrual or post-menopausal bleeding, or unexplained persistent unusual vaginal discharge? Those undergoing Test of Cure surveillance or have been treated for adenocarcinoma-in-situ Patients who have had a total hysterectomy with history of high-grade squamous intraepithelial tesion Patients who were exposed to diethylstibloestrol in utero. Management of participants in whom HPV is not detected Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to b				
Identifies HPV infection? Yes Yes No Indicated for Those who are eligible and due or overdue for cervical screening, including during pregnancy Other points in the pathway where only an HPV test is required. Patients who have postcoital, intermenstrual or post-menopausal bleeding, or unexplained persistent unusual vaginal discharge? Those undergoing Test of Cure surveillance or have been treated for adenocarcinoma-in-situ Patients who have had a total hysterectomy with history of high-grade squamous intraepithelial tesion Patients who were exposed to diethylstibloestrol in utero. Management of participants in whom HPV is not detected Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to b			Clinician-collected cervical sample	Self-collected vaginal sample
Indicated for adenocarcing for Indicated fo	Is it accurate?		Both methods have equivalent sensitivity for the detection of HPV and CIN2+/AIS ^{1,2}	
Indicated for Those who are eligible and due or overdue for cervical screening, including during pregnancy Other points in the pathway where only an HPV test is required. Patients who have postcoital, intermenstrual or post-menopausal bleeding, or unexplained persistent unusual vaginal discharge ² Those undergoing Test of Cure surveillance or have been treated for adenocarcinoma-in-stilu. Patients who have had a total hysterectomy with history of high-grades expansous intraepithelial tesion Patients who have had a total hysterectomy with history of high-grades expansous intraepithelial tesion Patients who were exposed to diethylstilboestrol in utero. Management of participants in whom HPV is not detected Amanagement of participants in whom HPV Inot 16/18] is detected Amanagement of participants in whom HPV Inot 16/18] is detected Amanagement of participants in whom HPV Inot 16/18] is detected Amanagement of participants in whom HPV Inot 16/18] is detected Amanagement of participants in whom Amanagement of participants in whom HPV Inot 16/18] is detected Amanagement of participants in whom Amanagement of participants i	Identifies HPV infection?		Yes	Yes
Pitose who are eligible and due or overdue for cervical screening, including during pregnancy Other points in the pathway where only an HPV test is required. Patients who have postocital, intermenstrual or post-menopausal bleeding, or unexplained persistent unusual vaginal discharge ³ Those undergoing Test of Cure surveillance or have been treated for adenocarcinoma-in-situ Patients who have had a total hysterectomy with history of high-grade squamous intrapelhteial tesion Patients who were exposed to diethylstitboestrol in utero. Management of participants in whom HPV is not detected Management of participants in whom HPV is of total form the patients of the patients	Is liquid-based cytology (LBC) and co-testing pos	sible?	Yes	No
bleeding, or unexplained persistent unusual vaginal discharge3 Those undergoing Test of Cure surveillance or have been treated for adenocarcinoma-in-situ Patients who have had a total hysterectomy with history of high-grade squamous intraepithelial lesion Patients who were exposed to diethylstilboestrol in utero. Management of participants in whom HPV is not detected -6% of CSTs Return in 5 years Return in 5 years Return in 5 years Return for clinician-collected cervical sample for LBC. The incidence of HPV [not 16/18] is highly age dependent [NCSR datad] 25-29 years 17% 50-54 years 4% 30-34 years 10% 55-59 years 3% 40-44 years 5% 65-69 years 3% 40-44 years 5% 65-69 years 3% Note: at the 12-month follow up HPV test after an Intermediate Risk result the incidence of HPV [not 16/18] is -60%4 Patients aged 70 to 74 with HPV [not 16/18] detected are referred to colposcopy.	Indicated for Those who are eligible and due or overdue for cervical screening, including during pregnancy Other points in the pathway where only an HPV test is required.		Yes	Yes
HPV is not detected Return in 5 years Return in 5 years Return for clinician-collected cervical sample for LBC. The incidence of HPV (not 16/18) is highly age dependent (NCSR data ⁴) 25-29 years 17% 50-54 years 4% 30-34 years 10% 55-59 years 3% 35-39 years 6% 60-64 years 3% 40-44 years 5% 65-69 years 3% 45-49 years 4% Note: at the 12-month follow up HPV test after an Intermediate Risk result the incidence of HPV (not 16/18) is -60% ⁴ Patients aged 70 to 74 with HPV (not 16/18) detected are referred to colposcopy. Management of participants in whom HPV (16/18) is detected Return in 5 years Return for clinician-collected cervical sample for LBC. The incidence of HPV (not 16/18) is highly age dependent (NCSR data ⁴) 25-29 years 17% 50-54 years 3% 40-44 years 5% 65-69 years 3% 40-44 years 5% 65-69 years 3% 45-49 years 4% Note: at the 12-month follow up HPV test after an Intermediate Risk result the incidence of HPV (not 16/18) detected are referred to colposcopy. Refer for colposcopy	Those undergoing Test of Cure surveillance or have been treated for adenocarcinoma-in-situ Patients who have had a total hysterectomy with history of		Yes	No
Management of participants in whom HPV (not 16/18) is detected Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Reflex LBC is performed on the original sample, no need to return for a further sample to be taken Note: at the 12-month follow up HPV test after an Intermediate Risk result the incidence of HPV (not 16/18) is -60%4 Patients aged 70 to 74 with HPV (not 16/18) detected are referred to colposcopy. Refer for colposcopy Refer for colposcopy	Management of participants in whom HPV is not detected	>90% of CSTs	Return in 5 years	Return in 5 years
HPV (16/18) is detected Refer for cotposcopy	Management of participants in whom HPV (not 16/18) is detected	~6% of CSTs		The incidence of HPV (not 16/18) is highly age dependent (NCSR data ⁴) 25-29 years 17% 50-54 years 4% 30-34 years 10% 55-59 years 3% 35-39 years 6% 60-64 years 3% 40-44 years 5% 65-69 years 3% 45-49 years 4% Note: at the 12-month follow up HPV test after an Intermediate Risk result the incidence of HPV (not 16/18) is ~60% ⁴ Patients aged 70 to 74 with HPV (not 16/18) detected are referred
Management of Unsatisfactory HPV test Repeat in 6 weeks Repeat at earliest convenience	Management of participants in whom HPV (16/18) is detected	~2% of CSTs	Refer for colposcopy	Refer for colposcopy
	Management of Unsatisfactory HPV test		Repeat in 6 weeks	Repeat at earliest convenience

CERVICAL SCREENING PATHWAY QUICK REFERENCE GUIDE









CERVICAL SCREENING PATHWAY (CLINICIAN-COLLECTED OR SELF-COLLECTED)

MORE INFORMATION:

For queries about clinical guidelines and management of patients please contact the VCS Pathology's Clinical Advisory Service.

Tel: (03) 9250 0309

The clinical guidelines are available at https://www.cancer.org.au/clinical-guidelines/cervical-cancer-screening

NCSP policies and resources are available at https://www.health.gov.au/ our-work/national-cervical-screeningprogram




Concor Council Australia Cennical Concor Screening Working Party, Clinical pathways. Convoid Screening pathway National Convoid Screening Programs Updatines for the management of Section distant all serioral billings, convening in regardless postations and invadigation of althoursel segment beging. Cancor Council Australia. Accessible from https://www.cancor.org.au/clinical-guidelines/convoid-cancor-screening Updated October 2002.



www.acpcc.org.au

Copyright Notice © 2026. Australian Centre for the Prevention of Cervical Cancer IACN 637 597 4368



RESOURCES FOR ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLE



NCSP Resources



How to collect your own sample (for Aboriginal and Torres Strait Islander women)



Video: How to collect your own sample (for Aboriginal and Torres Strait Islander women)



Brochure: Understanding your cervical screening test results



Fact Sheet: The Cervical Screening Test

https://www.health.gov.au/our-work/ncsp-healthcare-provider-toolkit/working-with-patients

RESOURCES FOR CULTURALLY AND LINGUISTICALLY DIVERSE PEOPLE



ACPCC

How To Take Your Own HPV Test





An information sheet for clinicians and patients, with step-by-step, illustrated instructions available in 20 languages.

www.acpcc.org.au/selfcollection-campaign


NCSP


Your Choices Explained





How To Take Your Own Sample





https://www.health.gov.au/our-work/ncsp-healthcare-provider-toolkit/working-with-patients

Understanding your Cervical Screening Test results



THANK YOU!











A joint Australian, State and Territory Government Program

